Selective photodetection and photodynamic therapy for prostate cancer through targeting of proteolytic activity

Molecular Cancer Therapeutics

Volumn 12, Issue 3, 2013, Pages 306-313

  Zuluaga, Maria Fernanda ^a   Sekkat, Nawal ^a   Gabriel, Doris ^a,c,d   Van Den Bergh, Hubert ^b   Lange, Norbert ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b EPFL   (Switzerland)

^c Massachusetts Institute of Technology Cambridge   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOTOSENSITIZING AGENT; POLYMERIC PROTEASE SENSITIVE PHOTOSENSITIZER; PRODRUG; UNCLASSIFIED DRUG; UROKINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER LOCALIZATION; CELL VIABILITY; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME ACTIVATION; FEMALE; FLUORESCENCE; HUMAN; HUMAN CELL; IN VIVO STUDY; IRRADIATION; MALE; MEMBRANE PERMEABILITY; MINIMALLY INVASIVE PROCEDURE; MOUSE; NONHUMAN; PHOTOACTIVATION; PHOTODYNAMIC THERAPY; PHOTOTOXICITY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; QUALITATIVE ANALYSIS; TUMOR LOCALIZATION; XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; CELL SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PRODRUGS; PROSTATIC NEOPLASMS; PROTEOLYSIS; TRANSPLANTATION, HETEROLOGOUS; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84874913116     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-0780     Document Type: Article

References (40)

1. Jemal A, Bray F, CenterMM,Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61: 69-90.
2. Ahmed HU, Pendse D, Illing R, Allen C, van der Meulen JH, Emberton M. Will focal therapy become a standard of care for men with localized prostate cancer? Nat Clin Pract Oncol 2007;4: 632-42.
3. Ahmed HU, Moore C, Emberton M. Minimally-invasive technologies in uro-oncology: the role of cryotherapy, hifu and photodynamic therapy in whole gland and focal therapy of localised prostate cancer. Surg Oncol 2009;18: 219-32.
4. Pinthus JH, Bogaards A, Weersink R, Wilson BC, Trachtenberg J. Photodynamic therapy for urological malignancies: past to current approaches. J Urol 2006;175: 1201-7.
5. Moore CM, Hoh IM, Bown SG, Emberton M. Does photodynamic therapy have the necessary attributes to become a future treatment for organ-confined prostate cancer? Br J Urol Int 2005;96: 754-8.
6. Windahl T, Andersson SO, Lofgren L. Photodynamic therapy of localised prostatic cancer. Lancet 1990;336: 1139.
7. Moore CM, Nathan TR, Lees WR, Mosse CA, Freeman A, Emberton M, et al. Photodynamic therapy using meso tetra hydroxy phenyl chlorin (mthpc) in early prostate cancer. Lasers Surg Med 2006;38: 356-63.
8. Zaak D, Sroka R, Höppner M, Khoder W, Reich O, Tritschler S, et al. Photodynamic therapy by means of 5-ala induced ppix in human prostate cancer - preliminary results. Med Laser Appl 2003;18: 91-95.
9. Lepor H. Vascular targeted photodynamic therapy for localized prostate cancer. Rev Urol 2008;10: 254-61.
10. Verigos K, Stripp DCH, Mick R, Zhu TC, Whittington R, Smith D, et al. Updated results of a phase I trial of motexafin lutetium-mediated interstitial photodynamic therapy in patients with locally recurrent prostate cancer. J Environ Pathol Toxicol Oncol 2006;25: 373-88.
11. Patel H, Mick R, Finlay J, Zhu TC, Rickter E, Cengel KA, et al. Motexafin lutetium-photodynamic therapy of prostate cancer: short- and longterm effects on prostate-specific antigen. Clin Cancer Res 2008;14: 4869-76.
12. Trachtenberg J, Bogaards A, Weersink RA, Haider MA, Evans A, McCluskey SA, et al. Vascular targeted photodynamic therapy with palladium- bacteriopheophorbide photosensitizer for recurrent prostate cancer following definitive radiation therapy: assessment of safety and treatment response. J Urol 2007;178: 1974-9.
13. Trachtenberg J, Weersink RA, Davidson SR, Haider MA, Bogaards A, Gertner MR, et al. Vascular-targeted photodynamic therapy (padoporfin, wst09) for recurrent prostate cancer after failure of external beam radiotherapy: a study of escalating light doses. Br J Urol Int 2008; 102: 556-62.
14. Arumainayagam N, Moore CM, Ahmed HU, Emberton M. Photodynamic therapy for focal ablation of the prostate. World J Urol 2010;28: 571-6.
15. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the epr effect in macromolecular therapeutics: a review. J Control Release 2000;65: 271-84.
16. Cozzi PJ, Wang J, Delprado W, Madigan MC, Fairy S, Russell PJ, et al. Evaluation of urokinase plasminogen activator and its receptor in different grades of human prostate cancer. Hum Pathol 2006; 37: 1442-51.
17. Zuluaga MF, Gabriel D, Lange N. Enhanced prostate cancer targeting by modified protease sensitive photosensitizer prodrugs. Mol Pharm 2012;9: 1570-9.
18. Gabriel D, Campo MA, Gurny R, Lange N. Tailoring protease-sensitive photodynamic agents to specific disease-associated enzymes. Bioconjug Chem 2007;18: 1070-7.
19. Sehgal I, Forbes K, Webb MA. Reduced secretion of mmps, plasminogen activators and timps from prostate cancer cells derived by repeated metastasis. Anticancer Res 2003;23: 39-42.
20. Forbes K, Gillette K, Kelley LA, Sehgal I. Increased levels of urokinase plasminogen activator receptor in prostate cancer cells derived from repeated metastasis. World J Urol 2004;22: 67-71.
21. Jenkins DE, Yu SF, Hornig YS, Purchio T, Contag PR. In vivo monitoring of tumor relapse and metastasis using bioluminescent pc-3mluc- c6 cells in murine models of human prostate cancer. Clin Exp Metastasis 2003;20: 745-56.
22. Chung DE, Kratz F. Development of a novel albumin-binding prodrug that is cleaved by urokinase-type-plasminogen activator (upa). Bioorg Med Chem Lett 2006;16: 5157-63.
23. Gerspach J, Nemeth J, Munkel S, Wajant H, Pfizenmaier K. Target-selective activation of a tnf prodrug by urokinase-type plasminogen activator (upa) mediated proteolytic processing at the cell surface. Cancer Immunol Immunother 2006;55: 1590-600.
24. Rono B, Romer J, Liu SH, Bugge TH, Leppla SH, Kristiansen PEG. Antitumor efficacy of a urokinase activation-dependent anthrax toxin. Mol Cancer Ther 2006;5: 89-96.
25. Barthel BL, Rudnicki DL, Kirby TP, Colvin SM, Burkhart DJ, Koch TH. Synthesis and biological characterization of protease-activated prodrugs of doxazolidine. J Med Chem 2012;55: 6595-607.
26. Choi Y, Weissleder R, Tung CH. Selective antitumor effect of novel protease-mediated photodynamic agent. Cancer Res 2006;66: 7225-9.
27. Campo MA, Gabriel D, Kucera P, Gurny R, Lange N. Polymeric photosensitizer prodrugs for photodynamic therapy. Photochem Photobiol 2007;83: 958-65.
28. Shariat SF, Roehrborn CG, McConnell JD, Park S, Alam N, Wheeler TM, et al. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. J Clin Oncol 2007;25: 349-55.
29. Ke SH, Coombs GS, Tachias K, Navre M, Corey DR, Madison EL. Distinguishing the specificities of closely related proteases. Role of p3 in substrate and inhibitor discrimination between tissue-type plasminogen activator and urokinase. J Biol Chem 1997;272: 16603-9.
30. Gabriel D, Zuluaga MF, Martinez MN, CampoMA, Lange N. Urokinaseplasminogen- activator sensitive polymeric photosensitizer prodrugs: design, synthesis and in vitro evaluation. J Drug Deliv Sci Tec 2009; 19: 15-24.
31. Momma T, Hamblin MR, Wu HC, Hasan T. Photodynamic therapy of orthotopic prostate cancer with benzoporphyrin derivative: local control and distant metastasis. Cancer Res 1998;58: 5425-31.
32. Chen B, Pogue BW, Zhou X, O'Hara JA, Solban N, Demidenko E, et al. Effect of tumor host microenvironment on photodynamic therapy in a rat prostate tumor model. Clin Cancer Res 2005;11: 720-7.
33. Koudinova NV, Pinthus JH, Brandis A, Brenner O, Bendel P, Ramon J, et al. Photodynamic therapy with pd-bacteriopheophorbide (tookad): successful in vivo treatment of human prostatic small cell carcinoma xenografts. Int J Cancer 2003;104: 782-9.
34. Fleshker S, Preise D, Kalchenko V, Scherz A, Salomon Y. Prompt assessment of wst11-vtp outcome using luciferase transfected tumors enables second treatment and increase in overall therapeutic rate. Photochem Photobiol 2008;84: 1231-7.
35. Madsen SJ, Sun CH, Tromberg BJ, Hirschberg H. Repetitive 5-aminolevulinic acid-mediated photodynamic therapy on human glioma spheroids. J Neurooncol 2003;62: 243-50.
36. Bogaards A, Varma A, Zhang K, Zach D, Bisland SK, Moriyama EH, et al. Fluorescence image-guided brain tumour resection with adjuvant metronomic photodynamic therapy: pre-clinical model and technology development. Photochem Photobiol Sci 2005;4: 438-42.
37. Hirschberg H, Sorensen DR, Angell-Petersen E, Peng Q, Tromberg B, Sun CH, et al. Repetitive photodynamic therapy of malignant brain tumors. J Environ Pathol Toxicol Oncol 2006;25: 261-79.
38. Zilidis G, Aziz F, Telara S, Eljamel MS. Fluorescence image-guided surgery and repetitive photodynamic therapy in brain metastatic malignant melanoma. Photodiagnosis Photodyn Ther 2008;5: 264-6.
39. Mathews MS, Angell-Petersen E, Sanchez R, Sun CH, Vo V, Hirschberg H, et al. The effects of ultra low fluence rate single and repetitive photodynamic therapy on glioma spheroids. Lasers Surg Med 2009; 41: 578-84.
40. Solban N, Selbo PK, Sinha AK, Chang SK, Hasan T. Mechanistic investigation and implications of photodynamic therapy induction of vascular endothelial growth factor in prostate cancer. Cancer Res 2006;66: 5633-40.